ImetelChat

I went through the K-10 and apart from some repetitive content from earlier K-10's there were some interesting things I picked out: - "We expect Janssen's decision-making regarding IMbark, IMerge, the imetelstat program or the Collaboration Agreement to occur in the second quarter of 2017." - "Secon...

My take aways from this abstract: - "In the combination group, 40% of treated mice were alive 77-days after treatment discontinued whereas all mice of the other single agent arms died within two weeks, demonstrating a significant survival benefit." - "a strong rationale for clinical exploration of t...

This is the full text of the abstract: Background/Aims: Acute myeloid leukemia (AML) is an aggressive cancer with limited treatment options outside of chemotherapy. Improved therapies with novel mechanisms of action are desperately needed to fill this need. Both hTERT, the catalytic subunit of telom...

My take aways from this abstract: - "In the combination group, 40% of treated mice were alive 77-days after treatment discontinued whereas all mice of the other single agent arms died within two weeks, demonstrating a significant survival benefit." - "a strong rationale for clinical exploration of t...

This is the full text of the abstract: Background/Aims: Acute myeloid leukemia (AML) is an aggressive cancer with limited treatment options outside of chemotherapy. Improved therapies with novel mechanisms of action are desperately needed to fill this need. Both hTERT, the catalytic subunit of telom...

Compare market cap: INCY 25Bln, GERN 350Mln. Just the MF market. Geron goes after hematologic malignancies, such as MF, PV, ET, MDS, CML and AML, because imetelstat targets the malignant clone and therefor offers disease modifying activity. Jakafi isn't capable of that. And there is pre-clinical evi...

ah, so I learned something. Kids keep us young!

Hunt, thanks for your nice words. Your posts are highly appreciated too. Please stay with us and see if we can increase our grip on this fascinating medicine!

@Jingled: what does 'k' means? Or did there something go wrong with your post?

jingled, I did a quick check. Patents can be filed and publicized in different geographical areas. The 14 May 2014 (Freshpatents) and the 6 Oct 2016 (Google patents) seem to be the same patent from Tefferi, but for different countries: https://www.google.com/patents/WO2015069758A1?cl=en&dq=Tefferi&h...

Bio, thanks for your nice and encouraging words. You could be right about the ending of IMbark. When I read Tefferi's patent one can argue that he has the key to fast approval: he found out how to safely administer imetelstat, he found out that imetelstat targets the malignant clones AND he found ou...

I corrected the publication date to prevent any misunderstandings.

Some people are playing chess and think many steps ahead. For sure, Tefferi had is act together already back in 2014. These patients are under the wings of Mayo and Tefferi. When asked about any update on these patients Dr.S. said that he hadn't been updated about them so he couldn't say anything mo...

USPTO Applicaton #: #20170051287 Filing date: 23 February 2017 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms. Summary of the invention: 'The invention provided herein discloses, inter alia, methods for using telomerase inhibitor compo...

It is certainly encouraging, because the patent actually is a confirmation that imetelstat works in a subset of patients. And Tefferi knows how to do it. What would the FDA say if he presents this to them? 44% overall response and 28%complete response? Plus a clear selection of patients who are like...

Sargasso, I don't think it is the same. The patent you are referring to is from Geron. Also the title is different. But it is interesting anyway, as I wasn't aware that Geron had a patent specifically targeting ET (although the patent seems to expand to other MPN's too). The biggest difference is th...

Thanks, jingled, for bringing this back. I made a separate topic of it, as you can see. It is a remarkable patent indeed, because it protects a method for using imetelstat for a predefined subgroup of patients. So it is criteria for patient selection + treatment method. Btw: I think you are referrin...

No illusions here. This is what Anna answered when I asked about this NCT02011126 trial: "The study you reference was going to be an investigator initiated study sponsored by the Children's Oncology Group, and was withdrawn several years ago, without being initiated. I don't know why the CT.gov entr...

Anna only can answer questions that provide an answer for public use. I don't think any question on what's going on with this trial will be answered, as this is all confidential. I took a look myself and I don't see the relevance of what has been updated. So the question for me is why they did these...

It's probably no coincidence that JnJ took AML for AACR. Who knows what response rate they found in their venetoclax/imet combo study. Looking forward to the abstract.

I have collected a few opinions from some of the experts from SA regarding the venetoclax - imet combo. This is an interesting video about venetoclax. The onco-community seems to be excited about this drug: http://www.onclive.com/peer-exchange/aml-precision-medicine/venetoclax-in-aml On SA there wer...